LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

2,579
Mkt Cap
$3.72B
Volume
88,329.00
52W High
$212.49
52W Low
$93.58
PE Ratio
91.00
LGND Fundamentals
Price
$189.07
Prev Close
$190.20
Open
$189.91
50D MA
$195.07
Beta
0.99
Avg. Volume
241,882.84
EPS (Annual)
-$0.2204
P/B
3.91
Rev/Employee
$2.46M
Loading...
Loading...
News
all
press releases
Moody Aldrich Partners LLC Buys Shares of 25,884 Ligand Pharmaceuticals Incorporated $LGND
Moody Aldrich Partners LLC bought a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Calamos Advisors LLC Grows Stake in Ligand Pharmaceuticals Incorporated $LGND
Calamos Advisors LLC lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 69.8% during the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·7h ago
News Placeholder
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 12.7% in the 3rd quarter, according to its most recent disclosure...
MarketBeat·5d ago
News Placeholder
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are presently covering the company...
MarketBeat·5d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance
Ligand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 7.400-7.650 for the period, compared to the consensus estimate of 4.370. The company...
MarketBeat·6d ago
News Placeholder
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Increased by Congress Asset Management Co.
Congress Asset Management Co. raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.0% in the third quarter, according to its most recent Form 13F...
MarketBeat·11d ago
News Placeholder
Woodstock Corp Sells 9,472 Shares of Ligand Pharmaceuticals Incorporated $LGND
Woodstock Corp lessened its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 32.1% in the third quarter, according to its most recent 13F filing with the...
MarketBeat·15d ago
News Placeholder
FY2026 Earnings Forecast for LGND Issued By Zacks Small Cap
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Analysts at Zacks Small Cap upped their FY2026 earnings per share estimates for Ligand Pharmaceuticals in a note issued to investors...
MarketBeat·15d ago
News Placeholder
Octavio Espinoza Sells 1,804 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 1,804 shares of the business's stock in a transaction dated Friday, December 12th. The shares were sold...
MarketBeat·15d ago
News Placeholder
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $339,711.24 in Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 1,804 shares of the company's stock in a transaction on Friday, December 12th. The shares were sold at an...
MarketBeat·16d ago
<
1
2
...
>

Latest LGND News

View

Advertisement|Remove ads.

Advertisement|Remove ads.